ClinicalTrials.gg
CompletedNCT01033526Updated Dec 16, 2009

Symptomatic Treatment of Common Cold Symptoms

A Phase 4 interventional study of Aspirin (Acetylsalicylic acid, BAYE4465) and Placebo in Common Cold, sponsored by Bayer. Completed at 28 sites in Italy. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2009-12-16.

Sponsored by Bayer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
388
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Common Cold with a site in Italy — none open to participants now, none under way, none of them phase 3. Common Cold · Italy.

Started
2005
with 1 other
Phase 4
Only one
of the 10
Registered
2nd of 10
by date
Lead sponsor
2 of 10
Bayer

Among the 10 studies in Common Cold with a site in Italy, this one is one of 2 that started in 2005, is the only one in phase 4, and was the 2nd registered.

Common Cold

219 studies on the registry are indexed under Common Cold; 23 are open to participants now.

Browse Common Cold studies →

Open to participants now

None of the 10 studies in Common Cold with a site in Italy is open now. The open studies under Common Cold, anywhere →

Who these studies take

Of the 14 Common Cold studies recruiting now, 4 (29%) set no upper age limit and 9 (64%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Common Cold with a site in Italy as a file.
02

Study summary

A two-arm, multicenter, randomized, double-blind, single dose placebo-controlled parallel groups study evaluating efficacy and tolerability of 800 mg Acetylsalicylic Acid (Aspirina C) in adult patients with a common cold during a two hour in patient phase; and a follow-up period of five days of home treatment as required.

03

Conditions studied

  • Common Cold

Browse trials for

Keywords

  • Symptomatic treatment of Common Cold symptoms
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 65 years
  • Onset of cold symptoms within 48 hours before screening
  • Objective symptoms of common cold
  • Subjective symptoms of common cold

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or lactation period
  • Active peptic ulcer
  • Hemorrhagic diathesis
  • History of chronic or recurrent ulcer disease or history of gastro-intestinal bleeding
  • to acetylsalicylic acid, to paracetamol, to any other component of the study medication, to anti-inflammatory or antirheumatic drugs, to other allergens
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
388 participants (actual)

Study arms

  • Placebo comparator
    Arm 2

    Drug: Placebo

  • Experimental
    Arm 1

    Drug: Aspirin (Acetylsalicylic acid, BAYE4465)

Interventions

  • 1-2 tablets Acetylsalicylic Acid 400 mg (in combination with Ascorbic Acid 240 mg) as needed every 4-6 hours over a maximum of 5 days

  • DrugPlacebo

    1-2 tablets matching Placebo as needed every 4-6 hours over a maximum of 5 days

06

What researchers measure

Primary outcomes

  1. Change in Cold Symptoms (patient Wisconsin Upper Respiratory Symptom Survey (WURSS domain 2 score) from baseline

    Time frame: 2 hours following intake of the first study medication dose

Secondary outcomes

  1. Changes in Common Cold Profile (sum of WURSS domains 1 182 3)

    Time frame: At each of five evenings during the follow-up period (or directly prior to the first intake of rescue medication during the follow-up period)

  2. Changes in Global Cold Severity (WURSS domain 1)

    Time frame: At each of five evenings during the follow-up period (or directly prior to the first intake of rescue medication during the follow-up period)

  3. Changes in Cold Symptoms (WURSS domain 2)

    Time frame: At each of five evenings during the follow-up period (or directly prior to the first intake of rescue medication during the follow-up period)

  4. Changes in Cold-specific Functional Impairments (WURSS domain 3)

    Time frame: At each of five evenings during the follow-up period (or directly prior to the first intake of rescue medication during the follow-up period)

  5. Changes in Global Cold Severity (WURSS domain 4)

    Time frame: At each of five evenings during the follow-up period (or directly prior to the first intake of rescue medication during the follow-up period)

  6. Adverse Event Collection

    Time frame: Until end of study

07

Study locations

28 sites
  • Borgo Di Terzo, Bergamo 24060, Italy
  • Brembate, Bergamo 24041, Italy
  • Calusco d'Adda, Bergamo 24033, Italy
  • Capriate San Gervasio, Bergamo 24042, Italy
  • Caravaggio, Bergamo 24043, Italy
  • Casazza, Bergamo 24060, Italy
  • Cologno Al Serio, Bergamo 24055, Italy
  • Covo, Bergamo 24050, Italy
  • Dalmine, Bergamo 24044, Italy
  • Mozzanica, Bergamo 24050, Italy
  • Ponte San Pietro, Bergamo 24036, Italy
  • Seriate, Bergamo 24068, Italy
  • Verdello, Bergamo 24049, Italy
  • Vertova, Bergamo 24029, Italy
  • Villa d'Adda, Bergamo 24030, Italy
  • Angera, Varese 21021, Italy
  • Carnago, Varese 21040, Italy
  • Cavaria, Varese 21044, Italy
  • Comerio, Varese 21025, Italy
  • Cunardo, Varese 21035, Italy
  • Fagnano Olona, Varese 21054, Italy
  • Induno Olona, Varese 21056, Italy
  • Sesto Calende, Varese 21018, Italy
  • Solbiate Olona, Varese 21058, Italy
  • Vedano Olona, Varese 21040, Italy
  • Vergiate, Varese 21029, Italy
  • Albano Sant'Alessandro, 24061, Italy
  • Varese, 21100, Italy
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2005 and a completion of Jun 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2009
First posted
Dec 16, 2009
Start
Oct 2005
CompletionActual
Jun 2007
Last update
Dec 16, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01033526
Lead sponsor
Bayer
First posted
Dec 16, 2009
Start date
Oct 2005
Completion
Jun 2007
Last update
Dec 16, 2009

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion